



MEDIA RELEASE

David Haylock, PhD Appointed as Chief Executive Officer

30 October, 2019; Melbourne, Australia: VivaZome Therapeutics Pty Ltd (“VivaZome”) is pleased to announce that Dr David Haylock has been appointed as Chief Executive Officer (CEO), effective as of 01 November, 2019.

Dr Haylock has collaborated with VivaZome since 2017 and joined the Company as Chief Scientific Officer (CSO) in July, 2019. In his role as CEO, Dr Haylock will maintain his CSO function.

Previously Dr Haylock has held senior leadership and management roles in organisations such as CSIRO, the Australian Stem Cell Centre, the Peter MacCallum Cancer Centre and the Institute for Medical and Veterinary Sciences. He has a wealth of experience in stem cell biology, cellular therapies and cell manufacturing, all of which are directly relevant to VivaZome’s exosome therapies.

“I am delighted to be given the opportunity to lead the VivaZome team as it explores this new field of therapeutics and develops cutting-edge technology”, stated Dr Haylock.

Executive Director, Craig Newton, said “I am excited to see David step up to the CEO role and have every confidence that he will take the Company to the next level over the coming years.”

Mr Newton will move to a non-Executive Director position with the Company as of 01 November.

For further information, contact:

VivaZome Therapeutics Pty Ltd
Dr Ian Nisbet, Chairman
ian.nisbet@vivazome.com
Phone: +61 (0) 431 709 121



About VivaZome Therapeutics Pty Ltd

VivaZome Therapeutics Pty Ltd (ABN 59 602 230 964) is a privately-held Australian biotech company, with headquarters at the La Trobe University Technology Enterprise Centre. VivaZome was formed to develop and commercialise exosome-based therapies for debilitating and/or life-threatening disorders, with an initial focus on critical limb ischaemia (CLI).

CLI is a debilitating disease caused by reduced blood flow, most often in the legs. It affects more than 4 million people worldwide, with an estimated treatment cost of over \$10B pa in the US alone. Existing treatments are largely surgical interventions including, in advanced disease, amputation. There is a huge need for new treatments, particularly pharmaceutical interventions to prevent or delay disease progression.

VivaZome is developing new technologies and generating intellectual property and proprietary materials that are applicable generically to exosome therapies. They will also underpin the Company's development of angiogenic exosomes for the treatment of CLI.

The VivaZome team has extensive expertise in the development and commercialisation of biological therapies, together with a wide network of expert contacts in the Australian and global biotech community.

For more information, visit www.vivazome.com.

About Exosomes

Exosomes are small particles released by cells. They are a key effector in communication between cells and have the potential to become an off-the-shelf medicine without the technical problems of cell therapies. Currently exosomes are made at small scale – the VivaZome project aims to develop a large-scale, advanced manufacturing process for exosomes.